Related Experiment Videos
Current progress in suicide gene therapy for cancer.
Kazuyuki Yazawa1, William E Fisher, F Charles Brunicardi
1Michael E. DeBakey Department of Surgery, Baylor College of Medicine, 6550 Fannin, Suite 1661, Houston, Texas 77030, USA.
World Journal of Surgery
|April 12, 2002
Summary
Suicide gene therapy targets cancer cells to convert prodrugs into chemotherapy, maximizing tumor destruction while minimizing harm to healthy cells. This approach shows promise in preclinical and early clinical studies for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Standard cancer treatments like chemotherapy and radiation target rapidly dividing cells.
- Tumor cells' higher division rate offers a therapeutic window for selective cancer cell damage.
- Suicide gene therapy aims to enhance this selectivity by targeting cancer cells specifically.
Purpose of the Study:
- To review and summarize the literature on suicide gene therapy for cancer treatment.
- To identify key suicide gene systems and delivery vectors used in this approach.
- To assess the efficacy and future potential of suicide gene therapy.
Main Methods:
- A literature search was performed using the MEDLINE database from 1990 to 2001.
- Articles related to suicide gene therapy for cancer were identified and reviewed.
- Various suicide gene systems and gene delivery vectors were cataloged.
Main Results:
- Several suicide gene systems were identified, including herpes simplex virus thymidine kinase (HSV-TK), cytosine deaminase, and nitroreductase.
- Commonly used vectors for gene transfer include liposomes, retroviruses, and adenoviruses.
- Suicide gene therapy strategies demonstrated effectiveness in cell cultures, animal models, and early clinical trials.
Conclusions:
- Suicide gene therapy offers a strategy to selectively kill cancer cells by converting prodrugs into active agents within the tumor.
- The identified gene systems and vectors have shown efficacy, suggesting therapeutic potential.
- Future advancements in targeted gene delivery, using specific promoters, are expected to further improve clinical applications of suicide gene therapy.